Trial Profile
Afatinib as first-line treatment for patient with advanced non-small cell lung cancer harbouring sensitizing EGFR mutations
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Oct 2019
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Sep 2019 Results assessing efficacy, side-effects and resistance mechanisms of first-line afatinib were presented at the 20th World Conference on Lung Cancer
- 11 Oct 2018 New trial record
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer